Proniras Corporation Analysis: $11M Raised
What is Proniras Corporation?
Clinical-stage biotech targeting opioid withdrawal with tezampanel
Location
Seattle, United States
Employees
1-10
Founded
2018
Product Features & Capabilities
- Tezampanel for opioid withdrawal treatment
- Clinical development of small-molecule therapeutics for CNS disorders
Use Cases
Treat opioid withdrawal symptoms in patients undergoing addiction therapy; Support clinical trials for tezampanel in Phase 1 studies; Develop treatments for related CNS disorders including seizure disorders
Other Considerations
Secured NIDA grant to support Phase 1 study; Raised Series B financing in 2024; Founded by Accelerator Life Science Partners; Based in Seattle, WA, US
See something that needs updating? Suggest edits to this profile.